Certara – Improving Investment in Drug Development through Biosimulation
Matthew Zierhut, Vice President, Integrated Drug Development discusses case studies that exemplify the importance of model-based meta-analysis and biosimulation in early-stage drug development to improve clinical trial success.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Healthcare. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Healthcare and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Healthcare?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
At Certara, Dr. Matthew Zierhut advances the integration of external aggregate clinical trial data into development decisions and commercial and regulatory strategy via model-based meta-analysis (MBMA). Matt works closely with clinical development teams to ensure MBMA is leveraged for optimal impact when making the most critical decisions
Previously, Matt was at Janssen (J&J) where over the past 5+ years he has led the development of their global MBMA capability and has worked together with many clinical development teams to ensure optimal impact of MBMA into the decision making in their programs. Prior to his time at Janssen, he held positions at Pfizer and Amylin as a pharmacometrician, implementing model-informed drug development strategies across a variety of programs and therapeutic areas. He started his professional career as a business consultant at Applied Predictive Technologies, where he designed and analyzed experimental trials to provide business recommendations for multiple Fortune 500 companies.
Matt received his PhD in Bioengineering from UC Berkeley and UCSF and holds an MBA from UC Berkeley, Haas School of Business.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
